Evidence map›Paper›PMID 37310551›Full record

ArticleCardiovascular drugs and therapy2024

Dual Versus Mono Antiplatelet Therapy in Patients with Acute Mild-to-Moderate Stroke: A Multicentre Perspective Cohort Study.

Kaili Zhang, Tingting Liu, Haimei Fan, Yongle Wang, Yanan Li, Juan Li, Yali Li, Yaqin Yu, Junhui Wang, Lixi Xue and 12 more

Abstract readMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Kaili ZhangDepartment of Neurology of Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.
Tingting LiuDepartment of Neurology, The First Hospital of Shanxi Medical University, Xiaoyuan Niu; 85 Jiefang South Road, Taiyuan, Shanxi, China.
Haimei FanDepartment of Neurology, The General Hospital of TISCO Affiliated to Shanxi Medical University, Taiyuan, China.
Yongle WangDepartment of Neurology, The First Hospital of Shanxi Medical University, Xiaoyuan Niu; 85 Jiefang South Road, Taiyuan, Shanxi, China.
Yanan LiDepartment of Neurology, The First Hospital of Shanxi Medical University, Xiaoyuan Niu; 85 Jiefang South Road, Taiyuan, Shanxi, China.
Juan LiDepartment of Neurology, The First Hospital of Shanxi Medical University, Xiaoyuan Niu; 85 Jiefang South Road, Taiyuan, Shanxi, China.
Yali LiDepartment of Neurology, The First Hospital of Shanxi Medical University, Xiaoyuan Niu; 85 Jiefang South Road, Taiyuan, Shanxi, China.
Yaqin YuDepartment of Neurology of Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.
Junhui WangDepartment of Neurology, Yanhu Branch First Hospital of Shanxi Medical University, Yuncheng, China.
Lixi XueDepartment of Neurology, Yanhu Branch First Hospital of Shanxi Medical University, Yuncheng, China.
Wenxian DuDepartment of Neurology, First People's Hospital of JIN ZHONG, Jinzhong, China.
Wenhua NiuDepartment of Neurology, First People's Hospital of JIN ZHONG, Jinzhong, China.
Yuping YanDepartment of Neurology, Taiyuan Wanbailin District Medical Group Central Hospital, Taiyuan, China.
Xiaolei GaoDepartment of Neurology, Taiyuan Wanbailin District Medical Group Central Hospital, Taiyuan, China.
Gaimei LiDepartment of Neurology, China Railway 17th Bureau Group Company Central Hospital, Taiyuan, China.
Qingping LiuDepartment of Neurology, China Railway 17th Bureau Group Company Central Hospital, Taiyuan, China.
Yuting LiuDepartment of Neurology, Shanxi cardiovascular hospital, Taiyuan, China.
Yanhong FanDepartment of Neurology of Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.
Jing RenDepartment of Neurology, Shanxi cardiovascular hospital, Taiyuan, China.
Xinyi LiDepartment of Neurology of Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.
Xuemei WuDepartment of Neurology, The General Hospital of TISCO Affiliated to Shanxi Medical University, Taiyuan, China.
Xiaoyuan NiuDepartment of Neurology, The First Hospital of Shanxi Medical University, Xiaoyuan Niu; 85 Jiefang South Road, Taiyuan, Shanxi, China. niuxiaoyuan1958@163.com.ORCID 0000-0002-0422-279X
Shanxi Medical University · CNChina Railway Group (China) · CNShanxi Cardiovascular Hospital · CNTaiyuan Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe purpose of this study was to evaluate the association between different antiplatelet therapy regimens and the functional outcomes and bleeding complications among mild-to-moderate ischaemic stroke patients based on real-world data.

methodsWe used data from the SEACOAST trial (Safety and efficacy of aspirin-clopidogrel in acute noncardiogenic minor ischaemic stroke) to analyse the data of patients with mild-to-moderate stroke within 72 h after onset who were treated with aspirin or clopidogrel alone or a combination of clopidogrel and aspirin from September 2019 to November 2021. Propensity score matching (PSM) was used to balance the differences between groups. We performed an analysis to evaluate the association of different antiplatelet regimens and 90-day disability, which was defined as a modified Rankin Scale score ≥2, as well as disability ascribed to index or recurrent stroke by the local investigator. In terms of safety, we then compared the bleeding events between the two groups.

resultsA total of 2822 mild-to-moderate ischaemic stroke patients were treated with either clopidogrel plus aspirin (n = 1726, 61.2%) or aspirin/clopidogrel (n = 1096, 38.8%). Of 1726 patients in the dual antiplatelet group, 1350 (78.5%) received less than or equal to 30 days of combined therapy. At 90 days, 433 (15.3%) patients were disabled. Patients who received combined therapy had a lower overall disability rate (13.7% versus 17.9%; OR 0.78 (0.6-1.01); P = 0.064). However, investigators found that index stroke was the reason for significantly fewer patients in the dual antiplatelet group having disability (8.4% versus 12%; OR, 0.72 (0.52-0.98); P = 0.038). There was no statistically significant difference in the incidence of moderate to severe bleeding complications between the dual and mono antiplatelet drug regimens (0.4% versus 0.2%; HR 1.5 (0.25, 8.98); P = 0.657).

conclusionAspirin plus clopidogrel was associated with a reduction in the incidence of disability attributed to index stroke. There was no statistically significant difference in the incidence of moderate to severe bleeding complications between the two antiplatelet drug regimens. TRIAL REGISTRATION NUMBER: ChiCTR1900025214.

Indexed as

AspirinClopidogrelDual Anti-Platelet TherapyHemorrhageIschemic StrokePlatelet Aggregation InhibitorsAgedDisability EvaluationDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRisk FactorsSeverity of Illness IndexStrokeAspirinClopidogrelPlatelet Aggregation InhibitorsAspirinClopidogrelDisabilityMild-to-moderate stroke

Identifiers

PMID37310551
OpenAlexW4380422293

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.